Profile data is unavailable for this security.
About the company
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
- Revenue in USD (TTM)0.00
- Net income in USD-16.37m
- Incorporated2020
- Employees8.00
- LocationPasithea Therapeutics Corp1111 Lincoln RoadMIAMI BEACH 33139United StatesUSA
- Phone+1 (786) 977-3380
- Websitehttps://www.pasithea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oragenics Inc | 7.47k | -19.52m | 4.05m | 5.00 | -- | -- | -- | 541.92 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Palisade Bio Inc | 0.00 | -14.17m | 4.07m | 9.00 | -- | 0.3342 | -- | -- | -20.07 | -20.07 | 0.00 | 10.30 | 0.00 | -- | -- | 0.00 | -90.97 | -132.36 | -109.07 | -165.45 | -- | -- | -- | -27,892.32 | -- | -972.73 | 0.0339 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| Azitra Inc | 408.20k | -9.96m | 4.08m | 10.00 | -- | 0.2976 | -- | 9.99 | -12.12 | -12.12 | 0.1151 | 1.80 | 0.0595 | -- | 1.83 | 40,820.00 | -145.30 | -- | -194.72 | -- | -- | -- | -2,440.46 | -- | -- | -- | 0.0191 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -3.45m | 4.09m | 5.00 | -- | 0.2075 | -- | -- | -3.89 | -3.89 | 0.00 | 14.99 | 0.00 | -- | -- | 0.00 | -5.54 | -40.33 | -6.89 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Enveric Biosciences Inc | 0.00 | -10.59m | 4.10m | 7.00 | -- | 0.6705 | -- | -- | -3.67 | -3.67 | 0.00 | 0.6862 | 0.00 | -- | -- | 0.00 | -133.67 | -104.94 | -206.10 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -28.37m | 4.13m | 22.00 | -- | 2.21 | -- | -- | -6.49 | -6.49 | 0.00 | 0.6142 | 0.00 | -- | -- | 0.00 | -133.45 | -61.43 | -167.53 | -68.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.03m | 4.14m | 3.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | 0.9986 | 0.00 | -- | -- | 0.00 | -139.98 | -104.18 | -163.33 | -111.05 | -- | -- | -- | -- | -- | -563.88 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Peak Bio Inc | 354.02k | -4.63m | 4.16m | -- | -- | -- | -- | 11.76 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.37m | 4.28m | 8.00 | -- | 0.2647 | -- | -- | -14.98 | -14.99 | 0.00 | 15.49 | 0.00 | -- | -- | 0.00 | -58.66 | -- | -62.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Oncternal Therapeutics Inc | 1.85m | -35.97m | 4.29m | 27.00 | -- | 0.2724 | -- | 2.32 | -12.19 | -12.19 | 0.6254 | 5.32 | 0.0495 | -- | -- | 68,370.37 | -96.40 | -49.40 | -116.52 | -54.51 | -- | -- | -1,948.70 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -29.11m | 4.31m | 7.00 | -- | -- | -- | -- | -0.5892 | -0.5892 | 0.00 | -2.54 | 0.00 | -- | -- | 0.00 | -90.03 | -83.69 | -119.01 | -97.54 | -- | -- | -- | -- | -- | -14.34 | 11.60 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Notable Labs Ltd | 313.00k | -16.74m | 4.39m | 16.00 | -- | 0.6103 | -- | 14.01 | -2.47 | -2.47 | 0.046 | 0.7439 | 0.0176 | -- | -- | 19,562.50 | -93.89 | -52.02 | -120.26 | -62.09 | 37.70 | 60.19 | -5,346.97 | -3,636.93 | -- | -- | 0.0405 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| CNS Pharmaceuticals Inc | 0.00 | -15.97m | 4.50m | 3.00 | -- | -- | -- | -- | -134.04 | -134.04 | 0.00 | -2.97 | 0.00 | -- | -- | 0.00 | -358.12 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Qualigen Therapeutics Inc | 0.00 | -9.27m | 4.51m | 4.00 | -- | -- | -- | -- | -1.66 | -1.75 | 0.00 | -0.445 | 0.00 | -- | -- | 0.00 | -134.64 | -- | -- | -- | -- | -- | -- | -- | -- | -9.64 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
Data as of Sep 23 2024. Currency figures normalised to Pasithea Therapeutics Corp's reporting currency: US Dollar USD
2.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adar1 Capital Management LLCas of 31 Mar 2024 | 27.70k | 2.66% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.35k | 0.13% |
| UBS Securities LLCas of 31 Mar 2024 | 608.00 | 0.06% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 250.00 | 0.02% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 150.00 | 0.01% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 6.00 | 0.00% |
| Jane Street Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Wells Fargo Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
